title: Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial.
abstract: BACKGROUND
  The pleiotropic effects of riluzole may antagonize common mechanisms underlying chronic cerebellar ataxia, a debilitating and untreatable consequence of various diseases.
  
  
  METHODS
  In a randomized, double-blind, placebo-controlled pilot trial, 40 patients presenting with cerebellar ataxias of different etiologies were randomly assigned to riluzole (100 mg/day) or placebo for 8 weeks. The following outcome measures were compared: proportion of patients with a decrease of at least 5 points in the International Cooperative Ataxia Rating Scale (ICARS) total score after 4 and 8 weeks compared with the baseline score; mean changes from the baseline to posttreatment ICARS (total score and subscores at 8 weeks); and occurrence of adverse events.
  
  
  RESULTS
  Riluzole and placebo groups did not differ in baseline characteristics. The number of patients with a 5-point ICARS drop was significantly higher in the riluzole group than in the placebo group after 4 weeks (9/19 vs 1/19; odds ratio [OR] = 16.2; 95% confidence interval [CI ] 1.8-147.1) and 8 weeks (13/19 vs 1/19; OR = 39.0; 95% CI 4.2-364.2). The mean change in the riluzole group ICARS after treatment revealed a decrease (p < 0.001) in the total score (-7.05 [4.96] vs 0.16 [2.65]) and major subscores (-2.11 [2.75] vs 0.68 [1.94] for static function, -4.11 [2.96] vs 0.37 [2.0] for kinetic function, and -0.74 [0.81] vs 0.05 [0.40] for dysarthria). Sporadic, mild adverse events occurred.
  
  
  CONCLUSIONS
  These findings indicate the potential effectiveness of riluzole as symptomatic therapy in diverse forms of cerebellar ataxia.
  
  
  METHODS
  This study provides Class I evidence that riluzole reduces, by at least 5 points, the ICARS score in patients with a wide range of disorders that cause cerebellar ataxia (risk difference 63.2%, 95% CI 33.5%-79.9%).
authors.affiliation: Center for Experimental Neurological Therapies, S. Andrea Hospital, II Faculty of Medicine, Sapienza University of Rome, Via di Grottarossa 1035-1039, 00189, Rome, Italy. giovanni.ristori@uniroma1.it
authors.forename: G
authors.initials: G
authors.lastname: Ristori
authors.forename: S
authors.initials: S
authors.lastname: Romano
authors.forename: A
authors.initials: A
authors.lastname: Visconti
authors.forename: S
authors.initials: S
authors.lastname: Cannoni
authors.forename: M
authors.initials: M
authors.lastname: Spadaro
authors.forename: M
authors.initials: M
authors.lastname: Frontali
authors.forename: F E
authors.initials: FE
authors.lastname: Pontieri
authors.forename: N
authors.initials: N
authors.lastname: Vanacore
authors.forename: M
authors.initials: M
authors.lastname: Salvetti
mesh_terms: D000328:Adult; D000368:Aged; D002524:Cerebellar Ataxia / Q000188:drug therapy*; D016001:Confidence Intervals; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D016017:Odds Ratio; D017063:Outcome Assessment, Health Care; D010865:Pilot Projects; D019782:Riluzole / Q000627:therapeutic use*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D018696:Neuroprotective Agents; D019782:Riluzole